Report Overview

The Australian Transthyretin Amyloidosis (ATTR) Therapeutics Market size stood at USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. ATTR amyloidosis is a medical disorder marked by the formation of abnormal deposits of a protein called amyloid (amyloidosis) in the organs and tissues of the body. It mostly affects the peripheral neuropathic or autonomic nervous system, as well as the cardiovascular system.

Due to the possibility of additional ATTR therapeutic drugs being introduced, increased healthcare awareness, and growing average income, the market is anticipated to rise significantly during the forecast period.



Market Drivers

The Transthyretin Amyloidosis Therapeutics market is expected to grow rapidly throughout the forecast period, owing to the likelihood of more ATTR therapeutic medicines being launched, more healthcare awareness, and rising average income.

Increasing usage of premium products including Vyndamax, Onpattro, other ATTR stabilizers & Fibril disruptors is among some of the key factors that is expected to drive market growth. Advances in therapeutical approaches and the continuous innovation of therapies are among other factors driving growth. Also, current treatment options are limited, compelling patients to rely on limited therapies.